Remove 2024 Remove BMI Remove Lipid disorders
article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

Getty Images milla1cf Fri, 03/08/2024 - 14:35 March 8, 2024 — Novo Nordisk today announced that the U.S. 1 The most common adverse event leading to discontinuation was gastrointestinal disorders, occurring in 10% of patients in the Wegovy group and 2% in the placebo group. Last accessed February 2024. mg and 36.4%

Obesity 111